Yescarta is the second gene therapy product approved in the U.S.
“How many different cell types are there in the human body? And how do these differences develop? Nobody really knows,” says Professor Stein Aerts from KU Leuven/VIB. But thanks to a new method developed by his team, that may be about to change.
The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2017 to
The device that was developed last year to provide wireless measurement of vital signs such as respiration and heartbeat has been downsized and further advanced.
Gunshot and Stabbing Victims More Likely to Die if Transported to the Trauma Center by Ambulance
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The conditional approval allows two U.S. sites to enroll up to five total patients. The FDA has also requested that the Company conduct additional device testing and address outstanding questions. Second Sight has 45 days to respond to FDA's requests.
A report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.